8-K: uniQure Announces Positive Interim Data for AMT-130 Huntington's Disease Gene Therapy

uniQure's AMT-130 gene therapy shows significant slowing of Huntington's disease progression and reduction in a key neurodegeneration marker in interim Phase I/II trial data.

Summary

• uniQure announced positive interim data from its Phase I/II clinical trials of AMT-130, a gene therapy for Huntington's disease.
• The data includes 24-month follow-up results from 21 patients across U.S. and European trials.
• A post-hoc statistical analysis compared treated patients to a propensity-weighted external control group of 154 patients.
• Patients receiving the high dose of AMT-130 showed an 80% slowing of disease progression as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS) compared to the control group.
• Patients receiving the low dose of AMT-130 showed a 30% slowing of disease progression compared to the control group.
• The study also showed a statistically significant 11% reduction in neurofilament light chain (NfL) in cerebrospinal fluid (CSF) in treated patients compared to baseline.
• AMT-130 was generally well-tolerated with a manageable safety profile, and no new AMT-130-related serious adverse events were reported.

Sentiment

Score: 8

Explanation: The document presents very positive interim results for a gene therapy targeting a severe disease with no current treatments. The statistically significant slowing of disease progression and reduction in a key biomarker are highly encouraging. The RMAT designation further boosts the positive outlook. However, the post-hoc analysis and unadjusted p-values temper the enthusiasm slightly.

Positives

• The high dose of AMT-130 showed a statistically significant 80% slowing of disease progression, indicating a strong potential therapeutic benefit.
• The reduction in CSF NfL levels suggests a positive impact on neurodegeneration.
• The therapy was generally well-tolerated with a manageable safety profile.
• The RMAT designation from the FDA could lead to an accelerated approval process.
• The company is planning to present further interim analysis in mid-2025 with 36-month data.

Negatives

• The statistical analysis was conducted post-hoc, which may introduce bias.
• The p-values used in the analysis were nominal and unadjusted.
• The low dose of AMT-130 did not show statistically significant slowing of disease progression.
• The data is still interim and may not be predictive of later results.

Risks

• The clinical trials may not demonstrate sufficient data to support further development.
• Interim data may not be predictive of later data readouts.
• Regulatory authorities may not accept the company's approach to using propensity-weighted external controls.
• The company may face challenges in conducting and funding a Phase III or confirmatory study.
• There are risks related to the company's ability to raise additional capital.

Future Outlook

uniQure plans to meet with the FDA to discuss expedited clinical development pathways, complete enrollment of a third cohort studying AMT-130 with immunosuppression, and present further interim data in mid-2025.

Management Comments

• Walid Abi-Saab, M.D., chief medical officer of uniQure, stated that the data demonstrates a statistically significant, dose-dependent slowing of the progression of Huntington's disease and lowering of NfL in the CSF at 24 months.
• Victor Sung, M.D., professor of neurology at the University of Alabama at Birmingham, stated that the preservation of motor and cognitive function combined with reduced NfL levels defy expectations about the natural progression of Huntington's disease.

Industry Context

This announcement is significant in the field of Huntington's disease research, as there are currently no approved therapies to slow the disease's progression. The positive results from uniQure's gene therapy could represent a major advancement in treatment options for this rare neurodegenerative disorder.

Comparison to Industry Standards

• The 80% slowing of disease progression with the high dose of AMT-130 is a significant result compared to the natural progression of Huntington's disease, which typically shows a decline over time.
• The reduction in CSF NfL levels is also notable, as an independent study showed a 26% increase in CSF NfL at 24 months in patients with early manifest Huntington's disease.
• While direct comparisons to other experimental therapies are difficult due to varying methodologies, the results suggest a potential for AMT-130 to be a leading treatment option.
• The use of a propensity-weighted external control group is a common approach in rare disease research, but the acceptance of this approach by regulatory authorities is not guaranteed.

Stakeholder Impact

• Shareholders may react positively to the encouraging clinical trial data and the RMAT designation.
• Patients with Huntington's disease and their families may have increased hope for a potential treatment.
• Employees of uniQure may be motivated by the positive results and the potential for a successful therapy.
• The scientific community may be interested in the findings and their implications for gene therapy research.

Next Steps

• uniQure expects to hold a meeting with the FDA in the second half of 2024 to discuss potential expedited clinical development pathways.
• The company plans to complete enrollment of the third cohort of the U.S. Phase I/II study exploring AMT-130 in combination with immunosuppression in the second half of 2024.
• uniQure anticipates presenting safety data from this cohort in the first half of 2025.
• The company expects to present another interim analysis from the ongoing Phase I/II studies of AMT-130 in mid-2025.

Key Dates

Keywords

Huntington's disease, gene therapy, AMT-130, clinical trial, neurodegeneration, RMAT, cUHDRS, NfL, FDA, biomarker